Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer. (ONCO S-O)
The choice of treatments for cancers by systemic way - chemotherapy, hormone therapy and targeted therapies - is currently defined by criteria for population groups and not to an individual. These expensive treatments - in financial terms and quality of life - will be effective for some and administered unnecessarily for other because there is no predictive test of response for a given individual.
For breast cancer, the usual treatment includes the first surgery and adjuvant therapies (chemotherapy, hormonal therapy ...) whose effectiveness will be assessed after many years as the occurrence or not of a recurrence or metastases.
These systemic treatments can also be administered before surgery to reduce the tumor volume and secondarily allow less mutilating surgery: it is the principle of treatment neo adjuvant. In this case, the efficiency will be evaluated more quickly.
In practice, a patient with breast cancer suspicion has a biopsy which confirms the diagnosis and defined the parameters (hormone receptors, cytological grade, receptor monoclonal antibodies ...) that guide to the most appropriate type of treatment.
Tumor size is evaluated in neo adjuvant pre-treatment by imaging: mammography, ultrasound and MRI.
At the end of this medication, the evaluation of the response is achieved by radiology and surgery.
Pathological examination evaluates and precise response by the criteria of Chevallier and / or Sataloff. An ex vivo test for predicting the response of cells to different chemotherapy regimens, the oncogramme, was developed by Oncomedics, a young company whose technology is derived from the University of Limoges.
Clinical response and / or histopathological could be compared in a reasonable time (2-6 months), the results of the oncogramme proposed by Oncomedics whether the efficiency obtained in vivo is that predicted by the ex vivo test.
It is the same in the metastatic setting when there is an available target for biopsy and assessment of response.
The management of ovarian cancer in advanced stages can also benefit from a radiological and histopathological evaluation strategy before and after systemic treatment to compare the in vivo results with those predicted by ex vivo by Oncomedics.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A fragment of Breast/Ovarian tumors will be taken from a specimen or a cold biopsy, tissue from patients diagnosed with breast cancer or ovarian cancer before starting an induction treatment stage IIIc and IV pleural IFGO operable.
- Culturing the cells obtained from the tumor fragment by Oncomedics in a defined medium and provided for enriching tumor cells compared to stromal cells.
- Maintaining the cells in culture for 7 days.
- Effects of conventional chemotherapy (corresponding to protocols) on these cells for 72 hours (growth chambers) by Oncomedics (chimio-oncogramme).
- For each chemotherapy tested, measuring the proportion of dead cells / total cells.
- Retained by Oncomedics results, not given to the nursing team. The patient will be treated and followed up in the usual way.
- At the end of the study, comparing the in vitro results (chimio-oncogramme) to the patient response to the same chemotherapy.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- University Hospital
-
Limoges, France, 87042
- University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age of at least 18 years.
- Patient with breast cancer needed starting an induction therapy or neo-adjuvant or metastatic but inoperable position (isolated bone metastases, skin permeation nodule).
- Patient Diagnosed with ovarian cancer before starting an induction treatment stage IIIc and IV pleural IFGO operable.
- Measurable disease according to RECIST 1.1 criteria by Magnetic resonance imaging (MRI), tomodensitometry scan or assessable by positron emission tomography scan (PET-SCAN) according to European Organisation for Research and Treatment of Cancer (EORTC) or Chevallier criteria and / or Sataloff post-neo adjuvant for breast or assessable during surgery for carcinomatosis by score Sugarbaker
- Patient has not expressed opposition to the use of their residual tumor
- Lack of cancer within 5 years with the exception of basal cell carcinoma or squamous cell cancer or in situ cervix Treaty
- Patients not included in a therapeutic trial with an experimental molecule in the indication concerned.
Exclusion Criteria:
- Lack of contraception for women of childbearing age
- Use of targeted therapy, hormone therapy, radiation therapy concomitantly
- Inability to submit to monitoring for geographical, social or psychological reasons
- Nobody deprived of liberty by administrative or judicial decision or person under guardianship.
- Difficulty understanding of the Protocol
- Social uninsured patient
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Oncogramme breast
Taking a fragment of breast tumors taken from a specimen.
Cells fragment are cultured for 7 days.
The effects of chemotherapy are studied on these cells through chimio-oncogramme
|
Cells fragment are cultured for 7 days.
The effects of chemotherapy are studied on these cells through chimio-oncogramme.
|
|
Oncogramme ovarian
Taking a fragment of ovarian tumors taken from a specimen.
Cells fragment are cultured for 7 days.
The effects of chemotherapy are studied on these cells through chimio-oncogramme
|
Cells fragment are cultured for 7 days.
The effects of chemotherapy are studied on these cells through chimio-oncogramme.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
In vitro analysis of chemotherapy responses
Time Frame: Days 7
|
Evaluate the predictive value of chemo-oncogramme on the patients response to the same (s) chemotherapy (s)
|
Days 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiological Evaluation of the in vivo response
Time Frame: Days 7
|
Radiological Evaluation of the in vivo response by RECIST or EORTC criteria
|
Days 7
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- I09018 (ONCOGRAMME S-O)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.